GeNeuro is a biotechnology company developing innovative treatments against inflammatory and degenerative disorders associated with endogenous retroviruses.
GeNeuro is committed to stopping neurodegenerative and autoimmune diseases through targeting causal factors of these pathologies by leveraging the emerging biology of human endogenous retroviruses.
GeNeuro was founded in 2006 and is headquartered in Geneva, Switzerland.
GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.
GeNeuro has already put temelimab through larger tests, most notably the 270-subject failed phase 2b and its slightly smaller extension study.
Geneuro is backed by Institut Mérieux and others. The company raised €17.5M in a latest financing on Jan 31, 2020.